Search Results

Aptevo Therapeutics Inc. today announced a presentation at The Essential Protein & Antibody Engineering Summit (PEGS) conference in Boston MA.

Aptevo Therapeutics Inc. today announced that it has entered into securities purchase agreements with certain healthcare-focused and institutional investors to purchase (i) 5,339,806 shares of its common stock.

Aptevo Therapeutics Inc. announced that the Company is participating in the BIO International Convention occurring June 3-6, 2024 in San Diego, CA.

Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced advancements in both clinical programs and one preclinical program.

Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today reported financial results for the quarter ended March 31, 2024 and provided a business update.

Aptevo Therapeutics Inc. today reported financial results for the year ended December 31, 2023 and provided a business update.

Aptevo Therapeutics Inc. today announced the pricing of a public offering of (i) 3,400,000 shares of its common stock or pre-funded warrants in lieu thereof and (ii) warrants to purchase up to an aggregate of 6,800,000 shares of its common stock.

Aptevo Therapeutics Inc. (NASDAQ:APVO) today announced the closing of its previously announced public offering of (i) 3,400,000 shares of its common stock or pre-funded warrants in lieu thereof and (ii) warrants to purchase up to an aggregate of 6,800,000 shares of its common stock (the “Common Warrants”) at a purchase price of $1.35 per share and associated Common Warrant.